CRISPR Therapeutics
CRSP
472 hedge funds and large institutions have $3.5B invested in CRISPR Therapeutics in 2023 Q4 according to their latest regulatory filings, with 120 funds opening new positions, 135 increasing their positions, 124 reducing their positions, and 45 closing their positions.
167% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 45
40% more capital invested
Capital invested by funds: $2.5B → $3.5B (+$1.01B)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
16% more funds holding
Funds holding: 406 → 472 (+66)
1.38% more ownership
Funds ownership: 69.09% → 70.47% (+1.4%)
9% more repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 124
1% more call options, than puts
Call options by funds: $304M | Put options by funds: $301M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$75.9M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
+$40.2M |
| 3 |
Morgan Stanley
New York
|
+$26.2M |
| 4 |
Jane Street
New York
|
+$19.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$23.9M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$13.8M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$13.5M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$12.6M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$12.5M |
CRSP Hedge Fund Activity: Q4 2023 in Review
472 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2023, worth a combined $3.5B — up 40% from $2.5B a quarter earlier.
Buyers outnumbered sellers: 120 funds opened new CRSP positions and 45 closed out — a net gain of 75 holders — while 135 added to existing stakes and 124 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $75.9M. The largest seller was Armistice Capital, cutting an estimated $23.9M.
- 472 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2023, up from 406 in Q3 2023.
- Funds reported $3.5B of CRISPR Therapeutics stock for Q4 2023, up 40% quarter-over-quarter.
- 120 funds opened new CRISPR Therapeutics positions in Q4 2023 and 45 closed out, a net change of +75 holders.
- The largest CRISPR Therapeutics buyer in Q4 2023 was ARK Investment Management, an estimated $75.9M added.
- The largest CRISPR Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $23.9M sold.
Based on aggregated 13F filings for Q4 2023.